生技药品开发和受託製造厂商市场按服务类型、表现系统、治疗类别、开发阶段和最终用户划分 - 全球预测 2025-2032

预计到 2032 年，生技药品受託製造厂商市场将成长至 191.8 亿美元，复合年增长率为 7.69%。

本文以精闢的视角，重点阐述了生技药品CDMO在技术、监管和商业性优势方面的伙伴关係和营运重点是如何演变的。

生技药品受託製造领域正经历一场策略重组，其驱动力来自技术进步、日益严格的监管要求以及愈演愈烈的竞争格局。各种规模的企业都在重新评估如何与外部製造商合作，将复杂的分子从发现阶段推进商业化阶段，同时也要应对供应链脆弱性和劳动力短缺等问题。先进的表达系统、不断发展的治疗模式以及研发人员的营运需求之间的相互作用，正在为品质、速度和灵活性设定新的标准，现有企业必须满足这些标准才能保持竞争力。

在此背景下，产业相关人员日益重视能够提供技术深度和商业性灵活性的端到端伙伴关係关係。包括原料药和製剂整合能力在内的创新服务模式正在重新定义客户期望，并推动研发阶段的快速前进。此外，对一次性技术、模组化设施和数位化流程控制的投资并非仅仅是成本控制策略，而是支持扩充性和合规性的策略推动因素。总而言之，这些因素正在显着改变申办方选择合作伙伴、建立合约和製定长期供应策略的方式，从而创造一个更具韧性、创新主导的市场环境。

快速的技术进步、策略整合以及赞助商期望的改变，正在生技药品生产领域创造新的竞争动态和伙伴关係模式。

随着申办者和服务供应商适应新的需求，生技药品生产生态系统正经历变革性的变化：更快的临床试验时间、更严格的监管审查以及需要灵活的生产能力来适应不同的给药方式。表现系统和下游製程的进步提高了产量和产品一致性，而分析和数位化製程监控技术的同步发展则提高了人们对可追溯性和品质保证的期望。这种技术变革与策略转变相辅相成：越来越多的申办者正从交易型外包转向策略合作，后者包括共同开发和风险共担机制。

同时，市场动态正在推动整合和专业化。大量策略性投资正涌向支持复杂单株抗体和细胞疗法供应链中哺乳动物细胞表达能力的建设，而一些专注于特定领域的供应商则凭藉优化的微生物系统，在快速重组蛋白生产方面脱颖而出。这种脱节促使申办方采用混合筹资策略，将灵活的小规模早期研发能力与强大的商业化规模合作伙伴结合，以支援后期生产。因此，长期供应商关係、平台技术投资以及区分表现系统和研发阶段的能力正成为竞争优势的核心决定因素。政策制定者和监管机构也在透过强调供应链透明度和品质指标来影响这一转变。

了解预期贸易政策变化和关税调整将如何改变生技药品研发和生产中的采购、产能分配和供应商策略

预计2025年关税波动和贸易政策调整将为生技药品供应链、筹资策略和跨境生产伙伴关係带来复杂的挑战。关税可能对关键原材料、一次性耗材以及灌装包装环节的某些组件的到岸成本产生重大影响，迫使企业重新评估采购区域和合约条款。为此，申办方和契约製造可能会加快供应商多元化，建立区域采购中心，或重新谈判长期供应协议，以降低潜在的成本波动并维持生产计划。

除了直接投入成本外，关税主导的变化也会对计划规划和产能分配产生间接影响。例如，某些设备和耗材进口关税的提高可能会促使企业将部分生产流程（尤其是那些涉及特殊法律规范或依赖低温运输的流程）迁回国内。此类措施可能会改变资本部署决策，使企业优先投资于模组化、可移动的资产，进而降低跨国关税风险。此外，随着企业寻求透过多段运输路线和本地化仓储来规避关税风险，物流可能会变得更加复杂。重要的是，监管合规仍然是不可妥协的。采购和製造地的调整必须考虑到检验要求和供应链透明度义务，以避免下游批准受阻。总而言之，週详的方案规划、灵活的合约条款以及加强与供应商的关係，将是减轻贸易政策变化对生技药品研发和商业化累积影响的关键工具。

细分市场分析表明，服务类型、表达平台、治疗领域、研发阶段需求和最终用户画像是驱动CDMO能力和策略重点的关键因素。

透过细緻的市场细分，我们发现不同服务类型、表达系统、治疗类别、研发阶段和最终用户的需求驱动因素、营运要求和价值提案有显着差异。根据服务类型，市场可分为产品服务和原料药服务，二者均需要独特的技术能力和监管流程，并导致不同的合作伙伴选择标准。在哺乳动物系统中，复杂的糖基化蛋白需要深厚的专业知识，例如细胞株、 细胞株和Ns0细胞株；而微生物方法，例如大肠桿菌和酵母，则擅长快速、经济高效地生产结构相对简单的分子。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 扩大细胞和基因疗法生产能力，以满足日益增长的个人化医疗需求
• 增加一次性生物反应器的使用，以提高操作灵活性并降低污染风险。
• 实施连续的上下游生物工艺，以缩短产品上市时间
• 将数位双胞胎技术整合到生物製药领域，用于即时监测和製程优化
• CDMO与製药创新者建立策略伙伴关係，以扩大抗体药物复合体
• 在生物製造中实施用于线上品管的先进製程分析技术平台
• 开发模组化设施设计，以实现多产品生物製药管线产能的快速扩张。
• 利用人工智慧驱动的预测性维护，最大限度地减少生物製药生产设施的非计划性停机时间
• 投资永续生产方法，以减少生物製药行业的水消费量和碳排放
• 随着重磅单株抗体专利到期，生物相似药合约服务应运而生。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章生技药品受託製造厂商市场（按服务类型划分）

• 製药
• 原料药

第九章生技药品合约开发及受託製造厂商市场（按表现系统）

• 哺乳动物
  • CHO细胞
  • HEK细胞
  • Ns0细胞
• 微生物
  • 大肠桿菌
  • 酵母菌

第十章生技药品受託製造厂商市场（按治疗类别划分）

• 免疫学
• 感染疾病
• 神经病学
• 肿瘤学

第十一章生技药品受託製造厂商市场（依开发阶段划分）

• 商业的
• 第一阶段
• 第二阶段
• 第三阶段
• 临床前

第十二章生技药品合约开发和受託製造厂商市场（按最终用户划分）

• 生技中小企业
• 合约研究组织
• 大型製药公司

第十三章生技药品合约开发与受託製造厂商市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章生技药品合约开发与受託製造厂商市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国生技药品合约开发与受託製造厂商市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Lonza Group AG
  • Catalent, Inc.
  • Samsung Biologics Co., Ltd.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • WuXi Biologics（Cayman）Inc.
  • Thermo Fisher Scientific Inc.
  • Fujifilm Diosynth Biotechnologies USA, Inc.
  • Patheon, Inc.
  • AGC Biologics Inc.
  • Merck KGaA

The Biologics Contract Development & Manufacturing Organization Market is projected to grow by USD 19.18 billion at a CAGR of 7.69% by 2032.

An incisive introduction highlighting how technological, regulatory, and commercial forces are reshaping biologics CDMO partnerships and operational priorities

The biologics contract development and manufacturing landscape is entering a period of strategic recalibration driven by technological advancement, heightened regulatory expectations, and intensified competitive dynamics. Organizations of all sizes are reassessing how they partner with external manufacturers to bring complex molecules from discovery through commercialization, while simultaneously navigating supply chain fragility and workforce constraints. The interplay between advanced expression systems, evolving therapeutic modalities, and the operational needs of developers has created new benchmarks for quality, speed, and flexibility that incumbent players must meet to remain relevant.

Against this backdrop, industry stakeholders increasingly prioritize end-to-end partnerships that deliver technical depth alongside commercial agility. Innovative service models, including integrated drug substance and drug product capabilities, are redefining customer expectations and enabling faster transitions across development phases. Furthermore, investments in single-use technologies, modular facilities, and digital process controls are not merely cost-management tactics but strategic enablers that support both scalability and regulatory compliance. Taken together, these forces are reshaping how sponsors select partners, structure contracts, and plan long-term supply strategies, setting the stage for a more resilient and innovation-driven market environment.

How rapid technological advances, strategic consolidation, and shifting sponsor expectations are creating new competitive dynamics and partnership models in biologics manufacturing

The biologics manufacturing ecosystem is experiencing transformative shifts as sponsors and service providers adapt to a new set of imperatives: faster time-to-clinic, higher regulatory scrutiny, and the need for flexible manufacturing capacity that supports diverse modalities. Advances in expression systems and downstream processing are enabling higher yields and greater product consistency, while parallel developments in analytics and digital process monitoring are elevating expectations for traceability and quality assurance. These technological shifts are complemented by strategic shifts: more sponsors are moving from transactional outsourcing to strategic alliances that embed co-development and risk-sharing arrangements.

Concurrently, market dynamics are driving consolidation and specialization. Large-scale strategic investments are being directed toward capacity that supports mammalian cell expression for complex monoclonal antibodies and cell therapy supply chains, while niche providers are differentiating through microbial systems optimized for rapid recombinant protein production. This divergence is prompting sponsors to adopt hybrid sourcing strategies that pair flexible, small-scale capacity for early-stage development with robust commercial-scale partners for later-stage manufacturing. As a result, long-term supplier relationships, investment in platform technologies, and the ability to pivot between expression systems and development phases are becoming core determinants of competitive advantage. Policymakers and regulators are also influencing these shifts by emphasizing supply chain transparency and quality metrics, which further shapes capital allocation and operational design across the sector.

Understanding how projected trade policy shifts and tariff adjustments could reshape sourcing, capacity allocation, and supplier strategies across biologics development and manufacturing

Anticipated tariff changes and trade policy adjustments in 2025 present a complex set of considerations for biologics supply chains, procurement strategies, and cross-border manufacturing partnerships. Tariffs can materially influence the landed cost of critical raw materials, single-use consumables, and certain components of fill-finish and packaging operations, leading organizations to reassess sourcing geographies and contractual terms. In response, sponsors and contract manufacturers may accelerate supplier diversification, establish regional sourcing hubs, or renegotiate long-term supply agreements to mitigate potential cost volatility and preserve production timelines.

Beyond direct input costs, tariff-driven shifts can have second-order effects on project planning and capacity allocation. For example, higher import duties on certain equipment or consumables could incentivize onshoring of specific manufacturing steps, particularly those with specialized regulatory oversight or cold-chain dependencies. Such moves would alter capital deployment decisions and may prioritize investments in modular, relocatable assets that reduce exposure to cross-border tariff risk. Additionally, logistics complexity may rise as firms seek to avoid tariff exposure through multi-leg routing or localized warehousing, which in turn creates operational friction and potential delays. Importantly, regulatory compliance remains non-negotiable; any adjustments to sourcing or manufacturing location must account for validation requirements and supply chain transparency obligations to avoid downstream approval setbacks. Overall, prudent scenario planning, flexible contract terms, and strengthened supplier relationships will be essential tools for mitigating the cumulative impacts of trade policy shifts on biologics development and commercialization.

Segmentation-driven insights revealing how service types, expression platforms, therapeutic focus, development phase needs, and end-user profiles dictate CDMO capabilities and strategic priorities

A nuanced segmentation lens reveals meaningful differences in demand drivers, operational requirements, and value propositions across service types, expression systems, therapeutic categories, development phases, and end users. Based on service type, the market distinguishes between drug product and drug substance services, each demanding specific technical capabilities and regulatory processes and prompting different partner selection criteria. Based on expression system, providers and sponsors evaluate trade-offs between mammalian and microbial platforms; mammalian systems require deep expertise in Cho, Hek, and Ns0 cell lines for complex glycosylated proteins, while microbial approaches such as E coli and yeast excel at rapid, cost-effective production for less complex molecules.

Based on therapeutic category, customer requirements vary significantly across immunology, infectious disease, neurology, and oncology, with oncology often necessitating highly tailored development pathways and immunology prioritizing robust scale-up capability. Based on development phase, needs evolve from preclinical and Phase I, where speed and flexibility are paramount, through Phase II and Phase III, where process robustness and scalable supply chain architectures become critical, to commercial stage where long-term capacity commitments, regulatory stability, and cost efficiency dominate decision criteria. Based on end user, expectations differ between biotech small and medium enterprises, contract research organizations, and large pharmaceutical firms; smaller biotech clients often prioritize agility and deep technical partnership, while large pharma typically seeks integrated global networks and stringent compliance systems. Together, these segmentation dimensions define the contours of demand and inform where investments in capability, quality systems, and commercial models will deliver the greatest strategic value.

Regional landscape analysis showing how the Americas, Europe Middle East & Africa, and Asia-Pacific each present distinct advantages and strategic considerations for biologics manufacturing

Regional dynamics continue to shape investment decisions, operational footprints, and partnership strategies across the global biologics manufacturing landscape. In the Americas, strengths include established regulatory frameworks, deep capital pools for facility expansion, and a concentration of sponsors requiring large-scale mammalian manufacturing capacity; this region often emphasizes integration with domestic clinical development programs and prioritizes supply chain resilience through localized capabilities. Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization efforts coexist with regional specialization, enabling a mix of high-quality contract services for both niche and commercial-scale programs and fostering collaboration across national centers of excellence.

Asia-Pacific is distinguished by rapid capacity growth, competitive cost structures, and an expanding pool of technical talent, making it an important hub for both early-stage development work and commercial manufacturing for export-oriented clients. However, cross-border regulatory alignment and technology transfer considerations remain important when leveraging regional capacity. Across all regions, stakeholders increasingly factor in geopolitical dynamics, logistics complexity, and the availability of skilled workforce when making siting and partnership decisions. Strategic regional diversification, coupled with adherence to global quality standards and proactive regulatory planning, helps sponsors manage operational risk while accessing the advantages each region offers for different phases of product development and commercialization.

Corporate strategies and capability-building trends among major and niche service providers that are driving competitive differentiation and long-term resilience in biologics manufacturing

Leading companies and innovative entrants are pursuing differentiated strategies to secure resilient revenue streams and technological leadership in biologics contract development and manufacturing. Many incumbent providers are expanding end-to-end capabilities to capture value across drug substance and drug product workflows, investing in modular facilities and single-use platforms to increase throughput flexibility while lowering up-front capital intensity. Others are focusing on specialized niches, such as advanced analytics, high-potency manufacturing, or gene and cell therapy supply chains, to command premium positioning where deep scientific expertise is a decisive competitive moat.

Strategic partnerships and alliance models are increasingly prominent, with sponsors seeking collaborators that can co-invest in platform development or capacity expansions. Digitalization and automation investments are being leveraged not only to increase operational efficiency but also to enhance data integrity, regulatory readiness, and remote process monitoring-capabilities that are especially attractive to global pharmaceutical clients. Talent and knowledge management remain critical differentiators; firms that combine robust training programs with cross-functional scientific teams are better positioned to support complex transfer projects and accelerated timelines. Finally, environmental, social, and governance priorities are becoming integral to corporate strategies, with sustainability initiatives increasingly influencing customer selection and long-term contractual negotiations.

Practical, high-impact actions that senior executives and operational leaders can implement to improve flexibility, reduce execution risk, and strengthen competitive positioning in biologics CDMO operations

Industry leaders can take decisive steps to preserve agility, manage risk, and capture growth opportunities in a rapidly evolving biologics manufacturing ecosystem. First, prioritize flexible platform investments that support multiple expression systems and scalable downstream processing to accommodate shifting client mixes and therapeutic modalities; such flexibility reduces revalidation burdens and shortens technology transfer timelines. Second, strengthen supplier relationships through multi-year strategic agreements with clear governance and contingency clauses that address trade policy volatility and raw material availability. Third, accelerate adoption of digital process control and advanced analytics to improve yield, reduce batch failures, and demonstrate superior data integrity to regulators.

In addition, diversify regional capacity strategically rather than uniformly, aligning facility types to regional advantages-early-phase development hubs in regions offering rapid turnaround and commercial-scale production in regions with proven regulatory alignment. Invest in workforce development and cross-training programs to mitigate talent bottlenecks and ensure continuity during scale-up or transfer activities. Finally, incorporate sustainability and ESG metrics into operational planning to meet emerging customer expectations and regulatory disclosure trends; this includes evaluating circular supply chain opportunities for single-use systems and reducing energy and water footprints where feasible. By implementing these measures, leaders can reduce execution risk, improve customer retention, and position their organizations for sustained competitiveness in a dynamic market.

A transparent and rigorous research methodology combining expert interviews, documentation review, and data triangulation to produce validated actionable insights for biologics manufacturing stakeholders

The research underpinning these insights was developed through a structured methodology that combined targeted primary engagement with subject-matter experts and rigorous secondary-source validation. Primary research included in-depth interviews with technical leaders, regulatory affairs professionals, and commercial executives across a spectrum of sponsors and service providers, enabling nuanced understanding of operational constraints and customer decision criteria. Secondary research involved a systematic review of regulatory guidance, patent landscapes, technology white papers, and publicly available company disclosures to contextualize primary findings and identify persistent industry patterns.

Data triangulation was applied throughout to reconcile divergent perspectives and validate conclusions, with special attention given to cross-referencing interview findings against facility filings, regulatory approvals, and equipment vendor capabilities. Segmentation mapping was employed to align capability indicators with service types, expression systems, therapeutic categories, development phases, and end-user profiles, ensuring that recommendations were grounded in empirically observed behaviors. Finally, limitations and potential biases were explicitly considered, including geographic sampling constraints and respondent confidentiality concerns, and were mitigated through methodological transparency and iterative validation with independent experts.

A concise conclusion emphasizing the strategic shifts, imperative investments, and collaborative approaches needed to thrive in the evolving biologics CDMO ecosystem

In conclusion, the biologics contract development and manufacturing sector is being reshaped by technological innovation, evolving sponsor preferences, and an increasingly complex geopolitical and regulatory environment. These forces are driving a shift toward more strategic, integrated partnerships and compelling service providers to invest in flexible platforms, enhanced analytics, and robust quality systems. Sponsors, in turn, are seeking partners that can balance speed with regulatory rigor and provide secure, diversified supply chains capable of supporting both rapid development and long-term commercialization.

Looking forward, organizations that proactively address tariff-driven supply risks, align regional investments with strategic therapeutic priorities, and adopt digital and sustainability-focused practices will be better positioned to meet the demands of next-generation biologics programs. Collaboration across the ecosystem-between technology vendors, contract providers, and sponsors-will be critical to accelerate capability development and to ensure that operational changes translate into reliable patient access. The collective ability to manage complexity while maintaining regulatory compliance and scientific excellence will determine which organizations emerge as preferred long-term partners in the biologics era.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Expansion of cell and gene therapy manufacturing capabilities to meet growing personalized medicine demand
• 5.2. Rise of single-use bioreactor adoption to drive operational flexibility and contamination risk reduction
• 5.3. Implementation of continuous upstream and downstream bioprocessing to accelerate time to market
• 5.4. Integration of digital twin technologies for real-time monitoring and process optimization in biologics
• 5.5. Strategic partnerships between CDMOs and pharmaceutical innovators for antibody-drug conjugate scale-up
• 5.6. Adoption of advanced process analytical technology platforms for inline quality control in biomanufacturing
• 5.7. Development of modular facility designs enabling rapid capacity expansion for multi-product biologic pipelines
• 5.8. Utilization of AI-driven predictive maintenance to minimize unplanned downtime in biologics production facilities
• 5.9. Investment in sustainable manufacturing practices to reduce water consumption and carbon emissions in biologics
• 5.10. Emergence of biosimilar contract services to capitalize on patent expirations of blockbuster monoclonal antibodies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Contract Development & Manufacturing Organization Market, by Service Type

• 8.1. Drug Product
• 8.2. Drug Substance

9. Biologics Contract Development & Manufacturing Organization Market, by Expression System

• 9.1. Mammalian
  • 9.1.1. Cho
  • 9.1.2. Hek
  • 9.1.3. Ns0
• 9.2. Microbial
  • 9.2.1. E Coli
  • 9.2.2. Yeast

10. Biologics Contract Development & Manufacturing Organization Market, by Therapeutic Category

• 10.1. Immunology
• 10.2. Infectious Disease
• 10.3. Neurology
• 10.4. Oncology

11. Biologics Contract Development & Manufacturing Organization Market, by Development Phase

• 11.1. Commercial
• 11.2. Phase I
• 11.3. Phase Ii
• 11.4. Phase Iii
• 11.5. Preclinical

12. Biologics Contract Development & Manufacturing Organization Market, by End User

• 12.1. Biotech Small Med
• 12.2. Contract Research Org
• 12.3. Large Pharma

13. Biologics Contract Development & Manufacturing Organization Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Biologics Contract Development & Manufacturing Organization Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Biologics Contract Development & Manufacturing Organization Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Lonza Group AG
  • 16.3.2. Catalent, Inc.
  • 16.3.3. Samsung Biologics Co., Ltd.
  • 16.3.4. Boehringer Ingelheim Pharma GmbH & Co. KG
  • 16.3.5. WuXi Biologics (Cayman) Inc.
  • 16.3.6. Thermo Fisher Scientific Inc.
  • 16.3.7. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • 16.3.8. Patheon, Inc.
  • 16.3.9. AGC Biologics Inc.
  • 16.3.10. Merck KGaA

LIST OF FIGURES

• FIGURE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 148. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
• TABLE 153. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 163. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 166. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 167. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
• TABLE 168. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
• TABLE 169. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 170. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 179. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 182. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 183. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
• TABLE 184. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2024 (USD MILLION)
• TABLE 190. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 227. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 230. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 231. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
• TABLE 232. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2032 (USD MILLION)
• TABLE 233. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 234. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 235. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 236. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 237. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGA